Stocktoria
Xencor Inc XNCR
Xencor Inc (XNCR) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $125.6M at a -73.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.576 |
| Retained earnings / assets | -0.909 |
| EBIT / assets | -0.203 |
| Equity / liabilities | 2.649 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| XNCR | Xencor Inc | 3/9 | 2.23 | — | +13.7% |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | 3/9 | -1.75 | — | +0.5% |
| ASRT | Assertio Holdings, Inc. | 2/9 | -6.37 | — | -5% |
| GYRE | GYRE THERAPEUTICS, INC. | 3/9 | 4.52 | 71 | +10.2% |
| URGN | UroGen Pharma Ltd. | 1/9 | -15.59 | — | +21.4% |
| TBPH | Theravance Biopharma, Inc. | 6/9 | 0.96 | 8.6 | +66.9% |
| ZVRA | ZEVRA THERAPEUTICS, INC. | 5/9 | -0.84 | 9 | +350.9% |
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
FAQ
Is XNCR financially healthy?
Xencor Inc's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does XNCR pay a dividend?
No, Xencor Inc does not currently pay a dividend.
How profitable is XNCR?
In FY2025, Xencor Inc had a net margin of -73.2% and a return on equity of -14.5%.
What is the analyst price target for XNCR?
The average Wall-Street price target for Xencor Inc is $28.50, about 23.0% above the recent price, from 12 analysts (consensus: strong buy).
Is XNCR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Xencor Inc: a Piotroski F-score of 3/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.